Goldman Sachs analyst Paul Choi suspended the firm's investment rating, price target, and earnings estimates for Gossamer Bio. Given the "going concern" warning within its financials and uncertainty of obtaining additional capital to fund operations, there is currently not sufficient basis for determining an investment rating, the analyst tells investors.
